Annovis Bio Inc
Annovis Bio Inc (ANVS) Historical Volatility
ANVS's 30 day historical volatility is 200.03%, in the 100th percentile of readings over the past year. This is a high percentile, meaning Annovis Bio Inc shares have swung far more than usual. ANVS's 30 day implied volatility sits at 9,489.19%, with an IV Rank of 85.32%, leaving IV 9,289.16 points above historical volatility. This means options are pricing in more movement than the stock has actually delivered, as of Nov 13, 2026.
Read more
Tracking ANVS historical volatility helps you see how much Annovis Bio Inc's stock price has actually moved, giving you a baseline for whether option premiums look fair, cheap, or expensive. While implied volatility shows what the market expects, ANVS's HV, also known as realized volatility, shows what actually happened. Use our scanner to monitor ANVS 30 day historical volatility alongside longer lookback windows and spot the moments when realized and implied diverge.
Historical volatility is the annualized standard deviation of a stock's past returns, typically measured over rolling windows like 10, 20, 30, or 60 days. ANVS's 30 day historical volatility, or ANVS HV, is one of the most widely watched readings because it balances responsiveness with stability. Comparing ANVS's HV to its implied volatility reveals the volatility risk premium. When IV sits well above HV, options are pricing in more movement than the stock has actually delivered, giving option sellers an edge. When HV runs hot relative to IV, options are pricing in less movement than the stock has delivered, and buyers may be underpaying for it.
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease in Down Syndrome and other chronic neurodegenerative disorders. It is also developing ANVS405 for protecting the traumatic brain injury and stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia.
Historical Volatility
Historical movement is elevated versus the past year. The stock has been unusually active.
As of Nov 13, 2026
As of Nov 13, 2026
As of Nov 13, 2026
Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →